Skip to Main Content

++

INTRODUCTION

++

becaplermin (be-kap-ler-min)

Regranex

Classification

Therapeutic: wound/ulcer/decubiti healing agent

Pharmacologic: platelet-derived growth factors

++
Indications
++

Treatment of lower extremity diabetic neuropathic ulcers extending to subcutaneous tissue or beyond and having adequate blood supply.

++
Action
++

Promotes chemotaxis of cells involved in wound repair and enhances formation of granulation tissue. Therapeutic Effects: Improved healing.

++
Adverse Reactions/Side Effects
++

Derm: erythematous rash at application site. Misc: MALIGNANCY (MAY LEAD TOMORTALITY, ESPECIALLY WITH USE OF ≥3 TUBES).

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess the size, depth, color, drainage, and periwound area to help document whether drug therapy is successful in promoting wound healing.

  • Monitor any new or increased skin reactions at the site of application, including rash, redness, and irritation. Be especially alert for any abnormal growth of tissues in/around the wound. Report any suspicious skin reactions to the physician.

++
Interventions
++

  • Implement wound-care procedures (whirlpool, pulsed lavage, gentle débridement) as needed to cleanse ulcers. Make sure the drug is reapplied and dressings are changed according to the recommended procedures.

  • When indicated, use appropriate physical agents (ultrasound, electric stimulation, ultraviolet light) to facilitate wound healing and augment drug effects.

  • Use assistive devices (walker, crutches) as needed to minimize weight bearing and help protect foot ulcers.

++
Patient/Client-Related Instruction
++

  • Check that the patient and family or caregivers understand topical application and wound-care procedures, and adhere to the recommended dosing schedule.

  • Instruct patient and family/caregivers about proper footwear, hygiene, and visual inspection to prevent recurrence or development of new ulcers.

++
Pharmacokinetics
++

Absorption: Minimal absorption (<3%).

++

Distribution: Action is primarily local.

++

Metabolism and Excretion: Unknown.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (improvement in ulcer healing)

ROUTE ONSET PEAK DURATION
topical within 10 wk unknown unknown

++
Contraindications/Precautions
++

Contraindicated in: Known hypersensitivity to becaplermin or parabens; Known neoplasm at site of application; Wounds that close by primary intention.

++

Use Cautiously in: Known malignancy; OB/Lactation/Pedi: Safety not established.

++
Interactions
++

Drug-Drug: None known.

++
Route/Dosage
++

Topical (Adults): Length of gel in inches from 15- or 7.5-g tube = length × width of ulcer area × 0.6; from the 2-g tube = length × width of ulcer area × 1.3. Length of gel in centimeters from 15- or 7.5-g tube = length × width of ulcer area ÷ 4; from the 2-g tube = length × width of ulcer area ÷ 2; for 12 hr each day.

++
Availability
++...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.